Specialized CRO Dintec Group Completes Series C Financing of Several Hundred Million RMB, Files for Hong Kong IPO

VCBeat has recently learned that Tripod Preclinical Research Laboratories Co., Ltd. (hereinafter referred to as “Tripod Group”) has announced the completion of its Series C financing round. The round was led by Legend Capital, with participation from CPIC Capital, Lingang Sci-Tech Innovation Investment, and Howbuy Fund. Existing shareholders, including Hui Capital, Hillhouse Ventures, Huaiji Investment, and Xiaochi Capital, continued their support through follow-on investments. This financing will empower Tripod Group to deepen its expertise in specialized therapeutic areas and commit to delivering non-clinical data with greater clinical value, thereby accelerating its international expansion in providing integrated preclinical-to-clinical R&D enablement for ophthalmology, central nervous system (CNS), and metabolic disease drug development.

Tripod Group was established in 2008, with a mission to focus on scientific evaluation, facilitate innovative translation, and improve quality of life.Headquartered in Nanjing, the Group has established subsidiaries in Nanjing, Kunming, Shanghai, Chengdu, Hainan, and other locations. Tripod Group boasts an internationally leading service provider for non-human primate disease model research, a top-tier GLP toxicology laboratory, China’s first AAALAC-accredited preclinical research institution specializing in medical devices, a domestically leading clinical analysis and testing service provider, and a clinical CRO company deeply engaged in specialized therapeutic areas, fostering in-depth collaborations with numerous outstanding enterprises both domestically and internationally.

Currently, Tripod Preclinical Research Laboratories Co., Ltd. (Tripod Group) is anchored in its core non-clinical research business and has extended horizontally across the entire industry chain, forming three major business segments: disease modeling and pharmacodynamics studies, regulatory strategy and safety assessment, and clinical and laboratory services. Supported by a high-quality and stable experimental animal supply system, Tripod provides integrated R&D enablement to global pharmaceutical companies and research institutions.

Zhang Xuefeng, CEO of Tripod Groupstated, “We are deeply honored to have earned the recognition of Legend Capital, CPIC Capital, Honghui Fund, Hillhouse Ventures, Lingang Sci-Tech Innovation Investment, Howbuy Fund, Huaiji Capital, and Xiaochi Capital. Tripod Group will strengthen resource restructuring, deepen our understanding of disease biological mechanisms and translational medicine, and focus on scientific assessment to enhance quality of life. Meanwhile, we will bolster our international competitiveness, collaborate with new drug R&D enterprises and relevant stakeholders, build a healthy ecosystem for the biopharmaceutical industry, and facilitate innovative translation.”

Zhou Hongbin, Co-Chief Investment Officer of Legend CapitalHe stated, “It is a great honor to participate in the endeavors of Tripod Group. We extend our gratitude to the company’s team and existing investors and shareholders for their support and recognition of Legend Capital. Legend Capital has long made systematic investments in the life sciences sector, emphasizing the linkage of industrial resources and professional empowerment. Tripod Group is an outstanding representative in China’s preclinical drug evaluation CRO field, focusing on one-stop CRO services for innovative drugs such as CGT (cell therapy and gene therapy), and has gained widespread recognition from global clients. Led by Mr. Zhang Xuefeng, the Tripod team is professional, dedicated, committed to high-quality service standards, and pursues ambitious career goals. We sincerely hope that Tripod Group will further rise to become a new type of CRO service provider with global influence.”

Jiangsu Tripod Preclinical Research Laboratories (Group) Co., Ltd. (hereinafter referred to as “Tripod Group”) was established in 2008. It is a novel contract research organization (CRO) dedicated to providing integrated R&D empowerment in specialized therapeutic areas for global pharmaceutical companies and research institutions. With a mission focused on rigorous scientific evaluation, facilitating innovative translation, and improving quality of life, Tripod Group leverages its top-tier technical service team with deep industry expertise. Through highly scientific and professional operational strategies, the company has built and refined a group-wide management system, focusing on deep empowerment spanning from disease mechanisms and disease models to non-clinical studies, clinical medicine, and clinical translation. Relying on exceptional service quality and extensive practical experience, Tripod Group supports technological innovation, leads industry transformation, and remains steadfastly committed to advancing human health.

Legend Capital, established in April 2001, is a leading professional investment firm in China specializing in early-stage venture capital and growth-stage private equity. Over its more than two decades of development, Legend Capital has adhered to international best practices, successfully managed multiple funds through their full life cycles, and delivered outstanding and sustainable fund performance. To date, it has invested in over 600 companies, with 106 achieving exits through initial public offerings (IPOs) on various global capital markets and nearly 100 exiting via mergers and acquisitions. Its portfolio includes world-class enterprises such as iFlytek, CATL, WuXi AppTec, and Pharmaron, as well as numerous national-level “Specialized, Refined, Differential, and Innovative” Little Giants and manufacturing single-product champions, thereby building a rich ecosystem of industrial resources. Staying true to its original mission, Legend Capital leverages capital and management expertise to foster corporate innovation and growth, drive industrial advancement, and promote social progress. While delivering strong financial returns, the firm actively fulfills its social responsibilities, striving for sustainable and high-quality development.

China Pacific Insurance (Group) Co., Ltd. (CPIC) is a leading comprehensive insurance group in China and the first insurance company to be listed in Shanghai, Hong Kong (China), and London (“A+H+G” shares). Through its subsidiaries, CPIC provides customers with comprehensive risk protection solutions, wealth planning, and asset management services. In 2021, it was included in the Fortune Global 500 for the eleventh consecutive year, ranking 158th. As the private equity fund management platform under the CPIC Group, CPIC Capital fully leverages the long-term and stable advantages of insurance funds, operates in a market-oriented manner, aligns with the Group’s strategic layout of “Greater Health, Greater Region, and Big Data,” proactively supports major national strategies, serves the development of the real economy, facilitates technological innovation among Chinese enterprises, and strives to achieve new breakthroughs on the path of high-quality development.

Serving China’s modernization, HLC is dedicated to discovering and realizing the enduring value of science and technology. Leveraging deep expertise in core disciplines such as chemistry, biology, and materials engineering, and grounded in independent, in-depth research and systematic empowerment services, HLC is committed to creating sustained positive impact on productivity transformation and improvements in public health through long-term value investments in the real economy and technological innovation. To date, HLC has invested in more than 120 high-quality companies, with 25 of them listed on stock exchanges both domestically and internationally. HLC manages dual-currency funds in RMB and USD, and maintains offices in Shanghai, Beijing, Shenzhen, and Hong Kong (China).